These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 1675013

  • 1. Surrogate markers for AIDS treatment.
    Jacobson M.
    Nurs Times; ; 87(22):49. PubMed ID: 1675013
    [No Abstract] [Full Text] [Related]

  • 2. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV.
    N Engl J Med; 1990 Jan 18; 322(3):166-72. PubMed ID: 1967191
    [Abstract] [Full Text] [Related]

  • 3. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J.
    BMJ; 1991 Jan 12; 302(6768):73-8. PubMed ID: 1671651
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Dis Markers; 1990 Jan 12; 8(3):164-5. PubMed ID: 2125538
    [No Abstract] [Full Text] [Related]

  • 5. [ Biological criteria for prediction of the clinical course leading to AIDS].
    Salmon D, Couroucé AM, Doinel C, Fine JM, Kaplan C, Lambin P, Lefrère JJ, Rouger P, Salmon C.
    Rev Fr Transfus Hemobiol; 1990 Dec 12; 33(6):407-14. PubMed ID: 1981002
    [No Abstract] [Full Text] [Related]

  • 6. Immune activation markers and AIDS prognosis.
    Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR.
    AIDS; 1991 May 12; 5(5):505-11. PubMed ID: 1677808
    [Abstract] [Full Text] [Related]

  • 7. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR, Lizioli A, Arcidiacono I, Cantaluppi P, Filippi C, Sobatti D, Bedarida G, D'Agostino F, Cambie G, Nardella ML.
    Boll Ist Sieroter Milan; 1990 Jun 12; 69(2):423-30. PubMed ID: 1983798
    [Abstract] [Full Text] [Related]

  • 8. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).
    Oie S, Jacobson MA, Abrams DI.
    J Acquir Immune Defic Syndr (1988); 1993 May 12; 6(5):531-3. PubMed ID: 8097790
    [No Abstract] [Full Text] [Related]

  • 9. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
    Siller L, Martin NL, Kostuchenko P, Beckett L, Rautonen J, Cheng SC, Wara DW.
    AIDS; 1993 Mar 12; 7(3):369-73. PubMed ID: 8097095
    [Abstract] [Full Text] [Related]

  • 10. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].
    Antón F, Labarga P, Pinilla J, Soto MJ, Leoz A, del Cura J, Borque L, Milazzo A.
    Enferm Infecc Microbiol Clin; 1993 Mar 12; 11(7):373-7. PubMed ID: 8104488
    [Abstract] [Full Text] [Related]

  • 11. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
    Reddy MM, McKinley G, Englard A, Grieco MH.
    Int J Immunopharmacol; 1990 Mar 12; 12(7):737-41. PubMed ID: 2127261
    [Abstract] [Full Text] [Related]

  • 12. Neopterin and beta-2 microglobulin levels in asymptomatic HIV infection: the predictive value of combining markers.
    Harrison NA, Skidmore SJ.
    J Med Virol; 1990 Oct 12; 32(2):128-33. PubMed ID: 2126281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The natural history and laboratory parameters of HIV infection].
    Brühwiler J, Lüthy R, Joller-Jemelka HI, Ledergerber B, Fierz W, Siegenthaler W, Grob PJ.
    Dtsch Med Wochenschr; 1989 Jun 30; 114(26):1015-20. PubMed ID: 2500318
    [Abstract] [Full Text] [Related]

  • 15. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH, van der Poll T, Mulder JW, Weverling GJ, Endert E, Lange JM, Sauerwein HP.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 15; 10(5):531-9. PubMed ID: 8548332
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of serum beta 2-microglobulin in HIV infection.
    Krämer A, Goedert JJ, Wachter H, Fuchs D.
    Lancet; 1992 Aug 08; 340(8815):371. PubMed ID: 1379663
    [No Abstract] [Full Text] [Related]

  • 17. [HIV infection and T-lymphocyte behavior: results of a study in Palermo].
    Cangelosi C, Giardina RA, Pecoraro G, Marcianò R, Vitale MG, Gullotti A, Caronia F, Spanò C.
    Ann Ig; 1989 Aug 08; 1(1-2):45-50. PubMed ID: 2483080
    [Abstract] [Full Text] [Related]

  • 18. The initial immune response to HIV and immune system activation determine the outcome of HIV disease.
    Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP.
    J Acquir Immune Defic Syndr (1988); 1991 Aug 08; 4(7):704-12. PubMed ID: 1675678
    [Abstract] [Full Text] [Related]

  • 19. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F, Vullo V, Cirelli A, Catania S, Mastroianni CM, Contini C, Delia S.
    Boll Ist Sieroter Milan; 1989 Aug 08; 68(2):115-21. PubMed ID: 2562362
    [Abstract] [Full Text] [Related]

  • 20. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
    Mulder JW, Lange JM, de Wolf F, Houweling JT, Bakker M, Coutinho RA, Goudsmit J.
    Neth J Med; 1990 Aug 08; 37(1-2):4-10. PubMed ID: 2120599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.